Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.

Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB.

Eur Neuropsychopharmacol. 2003 Mar;13(2):81-5.

PMID:
12650950
2.

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

Hum Psychopharmacol. 2003 Aug;18(6):457-61.

PMID:
12923824
3.

Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.

Assunção SS, Ruschel SI, Rosa Lde C, Campos JA, Alves MJ, Bracco OL, de Lima MS.

Rev Bras Psiquiatr. 2006 Dec;28(4):270-6. Erratum in: Rev Bras Psiquiatr. 2007 Mar;29(1):v.

4.

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.

Sacchetti E, Guarneri L, Bravi D.

Biol Psychiatry. 2000 Jul 15;48(2):167-8.

PMID:
10903413
5.

Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.

Pae CU, Kim JJ, Lee KU, Lee CU, Bahk WM, Lee SJ, Lee C, Paik IH.

Hum Psychopharmacol. 2003 Aug;18(6):453-6.

PMID:
12923823
6.

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.

Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A.

Am J Psychiatry. 2003 Feb;160(2):297-302.

PMID:
12562576
7.

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.

Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, Keith S.

Neuropsychopharmacology. 2003 Mar;28(3):527-9. Epub 2002 Oct 14.

8.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
9.

Nizatidine for the treatment of patients with quetiapine-induced weight gain.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N.

Hum Psychopharmacol. 2004 Jan;19(1):37-40.

PMID:
14716710
10.

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.

Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A.

Am J Psychiatry. 2002 Jun;159(6):1058-60.

PMID:
12042201
11.

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.

Conley RR, Mahmoud R.

Am J Psychiatry. 2001 May;158(5):765-74. Erratum in: Am J Psychiatry 2001 Oct;158(10):1759.

PMID:
11329400
12.

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A.

Arch Gen Psychiatry. 2000 Sep;57(9):841-9. Erratum in: Arch Gen Psychiatry 2002 Jan;59(1):91.

PMID:
10986547
13.

A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.

Rado J, von Ammon Cavanaugh S.

J Clin Psychopharmacol. 2016 Apr;36(2):163-8. doi: 10.1097/JCP.0000000000000469.

PMID:
26872112
14.

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.

Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A.

Eur Neuropsychopharmacol. 2004 Aug;14(4):332-6.

PMID:
15163444
15.

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.

Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine.

JAMA. 2003 Nov 26;290(20):2693-702.

PMID:
14645311
16.

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.

Am J Psychiatry. 2008 Mar;165(3):352-8. doi: 10.1176/appi.ajp.2007.07010079. Epub 2008 Feb 1.

PMID:
18245179
17.

Novel antipsychotics: comparison of weight gain liabilities.

Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR.

J Clin Psychiatry. 1999 Jun;60(6):358-63.

PMID:
10401912
18.

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.

Barak N, Beck Y, Albeck JH.

J Clin Psychopharmacol. 2016 Jun;36(3):253-6. doi: 10.1097/JCP.0000000000000489.

PMID:
27028981
19.

Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.

Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF.

J Clin Psychiatry. 2001 Apr;62(4):273-81.

PMID:
11379842
20.

Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Stauffer VL, Lipkovich I, Hoffmann VP, Heinloth AN, McGregor HS, Kinon BJ.

BMC Psychiatry. 2009 Mar 28;9:12. doi: 10.1186/1471-244X-9-12.

Supplemental Content

Support Center